03
Jun
Inclusion criteria were not specified in terms of the participants but it was clear that the review focused on HIV-infected patients with depressive symptoms. Another cohort study among pregnant women in Tanzania showed depressive symptoms among HIV-infected women were associated with a significantly increased risk of clinical disease progression to WHO HIVAIDS clinical stages III and IV 29.
1314 Depression can easily remain unrecognized and untreated.
Depression in hiv infected patients a review. Depression in HIV infected patients. Depression is the most common neuropsychiatric complication in HIV-infected patients and may occur in all phases of the infection. Accurately diagnosing major depressive disorder in the context of HIV is an ongoing challenge to clinicians and researchers being complicated by the complex biological.
Depression has long been recognized as a predictor of negative clinical outcomes in HIV-infected patients such as reducing medication adherence quality of life and treatment outcome and. Depression has long been recognized as a predictor of negative clinical outcomes in HIV-infected patients such as reducing medication adherence quality of life and treatment outcome and possibly worsening the progression of the illness and increasing mortality. By analyzing the most relevant studies MEDLINE EMBASE PsycLit Cochrane Library the review.
Depression in HIV Infected Patients. A Review Maria Giulia Nanni Rosangela Caruso Alex J. Mitchell Elena Meggiolaro Luigi Grassi Published online.
Depression has long been recognized as a predictor of negative clinical outcomes in HIV-infected patients such as reducing medication adherence quality of life and treatment outcome and possibly worsening the progression of the illness and increasing mortality. By analyzing the most relevant studies MEDLINE EMBASE PsycLit Cochrane Library the review discusses the epidemiology and the. Depression is the most common neuropsychiatric complication in HIV-infected patients and may occur in all phases of the infection.
Accurately diagnosing major depressive disorder in the context of HIV is an ongoing challenge to clinicians and researchers being complicated by the complex biological psychological and social factors associated with the HIV illness. Because there is a large overlap between HIV manifestations and somatic symptoms of anxiety and depression it is crucial to use measures that do not contain somatic items to validly and reliably assess these psychological states in HIV-infected patients. The purpose of this study was to assess the psychometric properties of the Hospital Anxiety and Depression Scale HADS a questionnaire that.
The incidence of some fatal diseases including HIVAIDS accompanied by depression has become a significant concern in developed developing and underdeveloped countries. A great deal of time and money are spent on controlling and reducing the complications of this infection across the world. Accordingly the main purpose of this study was to clarify the global prevalence rate of depression in patients living with HIVAIDS via a systematic review and meta-analysis.
In this study the prevalence of depression in HIV-infected patients was 21 comparable to previous reports for HIV-infected patients which observed prevalence typically ranging from 20 to 36. The estimated rate of depression among HIV-infected patients was higher than that among the general population. A recent review indicates that the point prevalence of depression in the general Korean population ranges from 76 to 169 and increases with age.
Major depression is a substantial burden to HIV-positive patients and the mental health needs of these patients are frequently unmet. There is evidence that depression is under-diagnosed and under-treated in HIV-positive patients 1 2. Approximately half of these patients do not receive treatment 3 6.
A review and update on HIV and depression reported a significant association between depressive symptoms and HIV progression. Another cohort study among pregnant women in Tanzania showed depressive symptoms among HIV-infected women were associated with a significantly increased risk of clinical disease progression to WHO HIVAIDS clinical stages III and IV 29. Major depressive disorder MDD has been the most extensively studied psychiatric comorbidity affecting HIV-infected patients with estimates of lifetime prevalence ranging from 4 to 45.
The wide variation in these prevalence rates is due to several factors including the patient population studied the practice setting and the method used to diagnose MDD. For example studies which rely on medical record. Depression is both a risk factor and a consequence of HIV infection.
1112 In PLWHA contributory factors for depression include comorbidities coping with the prospects of illness and death neurobiological changes related to persistent central nervous system CNS infections due to HIV social stigma sexual dysfunction and side effects of ART. 1314 Depression can easily remain unrecognized and untreated. A great deal of time and money are spent on controlling and reducing the complications of this infection across the world.
Accordingly the main purpose of this study was to clarify the global prevalence rate of depression in patients living with HIVAIDS via a systematic review and meta-analysis. Methodology All articles in English published between 2000 and 2018 were systematically searched. Depression and mortality in the HIV context.
Depression has been shown to increase the risk of mortality among PLWH 4195. For example among 1487 women followed for 24 months in Tanzania mortality was 66 among women with depressive symptoms versus 37 among women without depressive symptoms 66. Inclusion criteria were not specified in terms of the participants but it was clear that the review focused on HIV-infected patients with depressive symptoms.
Only one study required patients to have depression at study entry while two excluded patients with major depression. All but one study included only men. Outcomes assessed in the review.
We assessed the epidemiology of depression in HIV patients on antiretroviral therapy in a small urban setting in Cameroon by administering a structured interview for depression to 400 patients consecutively attending the Bamenda Regional Hospital AIDS Treatment Center.